Skip to Content

LX1033 Approval Status

LX1033 is an oral tryptophan hydroxylase inhibitor in development for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Development Status and FDA Approval Process for LX1033

Dec  3, 2013Lexicon Completes Phase 2 Study of LX1033 in IBS-D
Dec 17, 2012Lexicon's Drug Candidate For Irritable Bowel Syndrome (LX1033) Receives Fast Track Status From The FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.